Atrys Health (XMAD:ATRY) FFO


XMAD:ATRY Atrys Health SA XMAD:ATRY
68 GF Score
Price €2.57
GF Value €3.11
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health FFO?

FFO (Funds from operations) only applies to REITs.

XMAD:ATRY
68GF Score
Atrys Health SA XMAD:ATRY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.57 is trading 17.5% below its estimated GF Value™ of €3.11. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • FFO:
  • GF Value™: €3.11 vs. price of €2.57 (17.5% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
68GF Score

Get the complete analysis for XMAD:ATRY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.57
Price
€3.11
GF Value